1. Markov VA, Ryabov VV, Maximov IV, Vyshlov EV, Demyanov SV, Syrkina AG, Belokopytova NV, Shurupov VS, Oyunarov EO, Maximov AI, Vasilyev AG. Yesterday, today, tomorrow in diagnostics and treatment of acute myocardial infarction. Sib. Med. Zh. (Tomsk). 2011;26(2-1):8-13. Russian.
2. Maslov LN, Barbarash OL. Pharmacological approaches to limiting the infarct zone size in patients with acute myocardial infarction: analysis of clinical data. Eksp. Klin. Farmakol. 2018;81(3):34-41. Russian.
3. Barlow JJ, Blackburn TP, Costello GF, James R, Le Count DJ, Main BG, Pearce RJ, Russell K, Shaw JS. Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists. J. Med. Chem. 1991;34(11):3149-3158.
4. Birch PJ, Rogers H, Hayes AG, Hayward NJ, Tyers MB, Scopes DI, Naylor A, Judd DB. Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist. Br. J. Pharmacol. 1991;103(3):1819-1823.
5. Guo HT, Zhang RH, Zhang Y, Zhang LJ, Li J, Shi QX, Wang YM, Fan R, Bi H, Yin W, Pei JM. Endogenous κ-opioid peptide mediates the cardioprotection induced by ischemic postconditioning. J. Cardiovasc. Pharmacol. 2011;58(2):207-215.